Key Highlights

  • The third-quarter net loss widened to USD 17.8 million, or USD 0.36 per share, from USD 14.7 million, or USD 1.09 per share, a year earlier.
  • Cash, cash equivalents and marketable securities were USD 163.3 million at September 30, 2026, and management expects that balance to fund operations into 2029.
  • Research and development expenses rose to USD 15.1 million from USD 11.9 million, mainly on outsourced preclinical work and Manufacturing costs, while general and administrative costs were USD 4.3 million.
  • The company plans to file Investigational New Drug applications for OKI-345 in breast cancer and OKI-355 in vascular anomalies in the first half of 2027.

A Wider Loss Reflects Higher Preclinical Spending at OnKure Therapeutics (NASDAQ:OKUR)

OnKure Therapeutics (NASDAQ:OKUR) filed its Quarterly Report on November 4, 2026 for the period ended September 30. The clinical-stage company designs small molecules that target mutated forms of PI3Kα, a protein involved in cancer growth signaling, while sparing the normal version. Total operating expenses rose USD 3.9 million to USD 19.4 million, and interest income on its cash rose to USD 1.5 million from USD 0.8 million, which left the net loss at USD 17.8 million. The company has no approved products and has generated no product revenue. Over nine months, the net loss was USD 48.3 million versus USD 46.0 million, or USD 1.27 per share versus USD 3.41.

How a USD 150 Million Private Placement Changed the Funding Picture

On March 31, 2026, the company closed a private placement with gross proceeds of about USD 150.0 million before USD 9.6 million of fees and expenses. Investors bought 26.7 million shares at USD 4.15 each plus pre-funded warrants over 9.4 million shares, which were paid for at USD 4.1499 each at signing. The raise changed the going-concern assessment: at December 31, 2025, management had found substantial doubt about continuing operations, and following the placement it said that doubt was alleviated. The company also has an at-the-market sales agreement and a shelf registration for up to USD 200 million of securities.

Pipeline Timeline, Option Repricing and Remaining Dilution Risk

The company said it expects 2026 Research and Development expenses to exceed 2025 levels as it advances programs toward the planned 2027 filings. On August 7, 2026 it repriced Options covering about 1.7 million shares, previously set at USD 10.00 or more, to USD 4.14, the closing price that day, at an incremental cost of USD 1.6 million recognized over 12 to 18 months. The filing also states the company will need to raise substantial additional Capital to fund clinical trials, and Equity sales would dilute holders. Accumulated Deficit was USD 262.6 million at quarter end.

Where Things Stand

Cash appears sufficient for the stated plan, but only the plan. OnKure Therapeutics (NASDAQ:OKUR) holds USD 163.3 million and expects it to fund operations into 2029, which would cover the first half of 2027 filings for OKI-345 and OKI-355, yet the filing also says substantial additional capital will be needed for clinical trials. Spending is rising, with research and development up 26% (calculated) in the quarter. The next markers are those two Investigational New Drug submissions, the cash balance at year end, and any use of the at-the-market program.